Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026

Core Insights - InfuSystem Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has added two electronic infusion pumps to the list of qualifying products for separate payment under the NOPAIN Act, which aims to promote non-opioid pain management alternatives [1][4][8] Group 1: Regulatory Changes - The NOPAIN Act mandates separate Medicare payment for qualifying non-opioid treatments through December 31, 2027, when provided with a covered surgical procedure [4][8] - CMS confirmed that the CADD-Solis™ infusion pump and Eitan Medical's Sapphire™ infusion pump meet the qualifying requirements for separate payment under the NOPAIN Act, effective January 1, 2026 [5][6] Group 2: Financial Implications - The payment limitation for the infusion pumps is calculated at up to $1,997.16, with unique HCPCS codes assigned for claim submissions starting January 1, 2026 [7] - The new reimbursement structure is expected to encourage healthcare providers to consider adding InfuSystem's services to their formulary, potentially catalyzing volume growth in the Pain Management business [2] Group 3: Company Overview - InfuSystem is a leading national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers, operating under a two-platform model: Patient Services and Device Solutions [9]